Pfizer Inc. ranks slightly below the peer group median, with strong valuation offset by weak profitability. The trend is mixed and momentum is weakening. That creates a tension: current price behavior looks stronger than the structural profile would suggest.
Peer-relative scores, weakest to strongest
Pfizer is a global pharmaceutical company focused on the research, development, and commercialization of medicines and vaccines. Its portfolio spans major therapeutic areas, including oncology, immunology, and rare diseases.
A forward P/E of 9.8x—less than half the peer median—positions Pfizer at a clear discount, but this valuation gap reflects structural growth and quality deterioration. While the company maintains an operating margin of 23.9%, ongoing revenue contraction and a stagnant product pipeline have reduced market confidence, keeping the discount in place.
Internally, the -1.2% year-over-year revenue decline and a quality score of 34/100 (bottom third of the peer set) indicate stagnation. The market’s skepticism is further reflected in a maximum drawdown of -59%, indicating prolonged periods of underperformance. The operating margin appears stable, but this has not translated into renewed growth or peer-relative quality, leaving the core weakness unaddressed.
Recent external context complicates the picture rather than shifting it. Q4 2025 saw revenue down 5% year-over-year and EPS falling from $1.10 to $0.85, highlighting recent earnings pressure. Patent expirations on key drugs like Enbrel and Lyrica have exposed Pfizer to biosimilar competition, threatening future sales more than for peers with fresher portfolios. Regulatory scrutiny and looming pricing reforms in the US and EU add further margin risk, reinforcing the structural headwinds.
Compared to peers, Pfizer’s growth and quality metrics are more severely pressured than many sector names. While weak growth is not unique in the industry, the extent of Pfizer’s revenue contraction and patent cliff exposure is at the sharper end, especially versus companies like Qiagen (growth 62/100) and Hologic (quality 51/100). This pattern is partly driven by factors specific to Pfizer, such as its mature product mix and regulatory exposure.
A more constructive read would require revenue growth returning to positive territory versus peers and a clear easing of regulatory uncertainty. Supporting improvement would include successful launches of new patent-protected products. Until then, Pfizer appears as a name trading at a discount for understandable reasons.
Break down PFE's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.